Vol. 3 No. 3 (2023)
Reimbursement Recommendations

Lutetium (¹⁷⁷Lu) Vipivotide Tetraxetan (Pluvicto)

decorative image

Published March 22, 2023

Key Messages

  • CADTH recommends that Pluvicto should be reimbursed by public drug plans for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) if certain conditions are met.
  • Pluvicto should only be covered to treat patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who have received previous treatment with at least 1 androgen receptor pathway inhibitor (ARPI) and at least 1 taxane-containing regimen (i.e., chemotherapy), and who are in relatively good health (i.e., have good performance status).
  • Pluvicto should not be reimbursed in combination with anticancer therapies other than androgen-deprivation therapy (ADT), usage should be limited to 6 cycles, and the cost of Pluvicto should be reduced.